Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | June 08, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MYRIAD GENETICS INC
Report date June 08, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 171,889 |
Reported balance
After 2026-06-08 transaction · row 1
1 source rowRow 1 · 2026-06-08 · Sale · Disposed 15,000 · Balance 171,889 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.37 to $4.63, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.37 to $4.63, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 9, 2026 20:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 15,000 | $4.46 | $66,843.00 |
DisclosureSEC source: 0001824720-26-000004 · wk-form4_1781036444.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,889 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.37 to $4.63, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:24 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 59,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001824720-26-000002 · wk-form4_1780691088.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,889 F1 · shares: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:04 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 49,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029972 · wk-form4_1749240262.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,188 F1 · shares: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 7,500 | $28.01 | $210,075.00 |
DisclosureSEC source: 0001824720-24-000003 · wk-form4_1724186279.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,392 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027332 · wk-form4_1717793649.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,892 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001824720-23-000002 · wk-form4_1685744417.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,197 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 21:28 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 17,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-016224 · wf-form4_165429167498979.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,046 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:14 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 12,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001824720-21-000002 · edgardoc.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,771 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 15:29 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 23,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001824720-20-000005 · edgardoc.xml · nonDerivative · entry 1 Kumar Rashmi · CIK 0001824720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,923 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.